215798-19-9

Basic information

• Product Name: 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE
• Synonyms: 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE;6-Bromo-1,2,3,4-Tetrahydro-Isoquinolinehydrochlo;Isoquinoline, 6-broMo-1,2,3,4-tetrahydro-, hydrochloride (1:1);Isoquinoline, 6-broMo-1,2,3,4-tetrahydro-, hydrochloride;6-BroMo-1,2,3,4-tetrahydroisoquinoline hydrochloride, 4-tetrahydroisoquinoline hydrochloride
• CAS NO: 215798-19-9
• Molecular Formula: C₉H₁₀BrN*ClH
• Molecular Weight: 248.55
• EINECS: -0
• Mol File: 215798-19-9.mol

Chemical Properties

• Melting Point: 131-132 °C(Solv: ethanol (64-17-5))
• Boiling Point: 316.4 °C at 760 mmHg
• Flash Point: 145.1 °C
• Appearance: /
• Vapor Pressure: 0.000303mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE(215798-19-9)
• EPA Substance Registry System: 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE(215798-19-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 215798-19-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE is used as a therapeutic agent for its potential in treating neurological and psychiatric disorders. Its unique structure and properties allow it to modulate various biological pathways and target specific receptors, offering new avenues for the development of novel treatments.
Used as a Precursor in Synthesis:
In the pharmaceutical industry, 6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE serves as a precursor in the synthesis of other pharmaceutical compounds. Its versatile chemical structure allows for the creation of new molecules with potential therapeutic applications, contributing to the discovery and development of innovative drugs.
Used in Medicinal Chemistry Research:
6-BROMO-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE is utilized as a research tool in medicinal chemistry to explore its pharmacological properties and potential applications. Its unique structure and reactivity make it an interesting candidate for studying various biological interactions and mechanisms, furthering our understanding of its therapeutic potential.

InChI:InChI=1/C9H10BrN.ClH/c10-9-2-1-8-6-11-4-3-7(8)5-9;/h1-2,5,11H,3-4,6H2;1H

Upstream product

• 147497-32-3 6-bromo-3,4-dihydroisoquinolin-1(2H)-one 
• 893566-74-0 6-bromo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1189171-86-5 6-bromo-2-tert-butyl-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 1332301-98-0 3-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)-2-methylbenzamide 
• 1258852-58-2 3-[6-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl]propanamide 
• 1258440-75-3 1,1-dimethylethyl 6-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 1258440-17-3 2-[(1-methylethyl)oxy]-5-[5-(1,2,3,4-tetrahydro-6-isoquinolinyl)-1,3,4-thiadiazol-2-yl]benzonitrile 
• 893566-72-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1181690-12-9 (R)-6-(4-(2-(2-methylpyrrolidin-1-yl)ethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline 
• 893566-74-0 6-bromo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1181692-22-7 (R)-1-(6-(3-fluoro-4-(2-(2-methylpyrrolidin-1-yl)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone trifluoroacetate 
• 1181692-15-8 2-hydroxy-1-(6-(4-(2-(piperidin-1-yl)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone trifluoroacetate 
• 1181690-16-3 (R)-2-hydroxy-1-(6-(4-(2-(2-methylpyrrolidin-1-yl)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone hydrochloride 
• 1181691-16-6 2-oxo-2-(6-(4-(2-(tosyloxy)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl acetate 
• 1181691-17-7 2-oxo-2-(6-(4-(2-(piperidin-1-yl)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl acetate 
• 1181691-14-4 2-(6-(4-(2-(tert-butyldimethylsilyloxy)ethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl acetate 
• 1181691-15-5 2-(6-(4-(2-hydroxyethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl acetate 

Relevant articles and documents

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

A practical procedure for reduction of primary, secondary and tertiary amides to amines

A mild and general procedure for reduction of primary, secondary, and tertiary amides using catalytic triruthenium dodecacarbonyl and 1,1,3,3-tetramethyldisiloxane as reductant is described. The reaction is tolerant of numerous functional groups, and the amine products can often be isolated by direct crystallization as hydrochloride salts. The catalyst and silane are commercially available, air stable, and inexpensive, making the procedure accessible for both laboratory and large-scale applications. Copyright

Convenient Synthesis of 6-Bromo-1,2,3,4-tetrahydroisoquinoline and 3-Methoxy-1,2,3,4-tetrahydro-[2,7]-naphthyridine via Reductive Amination of Schiff's Bases

Synthesis of 7-bromo-1,2,3,4-tetrahydroisoquinoline and 6-methoxy-1,2,3,4-tetrahydro-[2,7]-naphthyridine via lithiation of 2-methylarylidene-tert-butylamines, followed by formylation, reductive amination in one-pot, and removal of the tert-butyl group fro